share_log

DEF 14A: Definitive information statements

DEF 14A: Definitive information statements

DEF 14A:股東委託書決議
美股SEC公告 ·  12/06 21:31

Moomoo AI 已提取核心訊息

Conduit Pharmaceuticals Inc. will hold a virtual special meeting of stockholders on January 9, 2025 to approve the issuance of shares related to warrant exercises and note conversions. Shareholders will vote on issuing up to 2,862,596 shares for warrant exercises, 75 million shares for converting a senior secured note, and 58 million shares for converting a convertible note.The company is seeking approval to comply with Nasdaq rules regarding potential issuance of 20% or more of outstanding shares. If approved, the conversions could significantly dilute existing shareholders. Conduit faces penalties if the meeting is not held by January 9, 2025.The proposals relate to financing arrangements made in late 2024, including a bridge loan, senior secured note, and convertible note. Management recommends shareholders vote in favor of all proposals to provide the company with financial flexibility.
Conduit Pharmaceuticals Inc. will hold a virtual special meeting of stockholders on January 9, 2025 to approve the issuance of shares related to warrant exercises and note conversions. Shareholders will vote on issuing up to 2,862,596 shares for warrant exercises, 75 million shares for converting a senior secured note, and 58 million shares for converting a convertible note.The company is seeking approval to comply with Nasdaq rules regarding potential issuance of 20% or more of outstanding shares. If approved, the conversions could significantly dilute existing shareholders. Conduit faces penalties if the meeting is not held by January 9, 2025.The proposals relate to financing arrangements made in late 2024, including a bridge loan, senior secured note, and convertible note. Management recommends shareholders vote in favor of all proposals to provide the company with financial flexibility.
Conduit Pharmaceuticals Inc. 將於2025年1月9日召開虛擬特別股東會議,以批准與認股權證行使和票據轉換相關的股份發行。 股東將投票批准發行最多2,862,596股用於認股權證行使,7500萬股用於轉換高級擔保票據,以及5800萬股用於轉換可轉換票據。該公司正在尋求批准以遵守納斯達克關於可能發行20%或以上流通股的規則。如果獲得批准,轉換將顯著稀釋現有股東的權益。如果會議未能在2025年1月9日之前召開,Conduit 將面臨處罰。這些提案與2024年末進行的融資安排有關,包括過渡貸款、高級擔保票據和可轉換票據。管理層建議股東支持所有提案,以爲公司提供財務靈活性。
Conduit Pharmaceuticals Inc. 將於2025年1月9日召開虛擬特別股東會議,以批准與認股權證行使和票據轉換相關的股份發行。 股東將投票批准發行最多2,862,596股用於認股權證行使,7500萬股用於轉換高級擔保票據,以及5800萬股用於轉換可轉換票據。該公司正在尋求批准以遵守納斯達克關於可能發行20%或以上流通股的規則。如果獲得批准,轉換將顯著稀釋現有股東的權益。如果會議未能在2025年1月9日之前召開,Conduit 將面臨處罰。這些提案與2024年末進行的融資安排有關,包括過渡貸款、高級擔保票據和可轉換票據。管理層建議股東支持所有提案,以爲公司提供財務靈活性。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息